\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationHybrid event
The 2023 European Institute for Innovation through Health Data (i~HD) conference will provide participants with a broader scope for enabling trust in the secondary use of health data. i~HD will present its holistic view showing all important health data challenges to be solved in order to trustworthy use and reuse of high-quality data to continuously improve care and accelerate research.
Making a comeback in the i~HD conference is “Joining the Dots” where European funded projects tackling health data challenges will be brought together. Use cases, insights, successes and challenges will once again be front-and-centre as experts lead the sessions.
More information, the detailed programme and registration on the conference website.
Please be aware this is a paying event. Please make sure to check the ticket price before registry. You can opt for virtual participation or for on-site participation (including an optional social programme).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
